経口タンパク質とペプチドの世界市場レポート 2025年

経口タンパク質とペプチド市場規模は、今後数年間で飛躍的な成長が見込まれます。2029年にはCAGR22.3%で34億9,000万米ドルに成長します。予測期間の成長は、患者中心の医薬品への注目の高まり、老年人口の増加、ヘルスケア支出の増加、がんにおける診断のニーズの高まり、経口薬への嗜好の高まりに起因すると考えられます。予測期間における主な動向としては、安定性と有効性を高めた新規経口ペプチドの開発、経口製剤の創薬プロセスにおける人工知能の統合、先進医療、ドラッグデリバリー技術の進歩、革新的な経口インスリン製剤などが挙げられます。

拡大するバイオ医薬品産業は、今後の経口タンパク質とペプチド市場の成長を牽引すると予想されます。この分野は、より広範な製薬産業の一部であり、生物由来の医薬品の開発、生産、商業化に重点を置いています。バイオ医薬品産業の成長は、バイオテクノロジーの進歩、個別化医療への需要の増加、慢性疾患の増加、研究開発への投資の増加によって促進されています。経口タンパク質とペプチドは、非侵襲的な治療デリバリーの可能性を提供し、患者のコンプライアンスを向上させ、注射の必要性を減らします。消化器系での安定性と吸収性を高め、特定の疾患をターゲットにすることができます。例えば、2023年6月、欧州製薬団体連合会（EFPIA）は、欧州におけるバイオ医薬品の総生産額が2022年に3,842億米ドル（3,400億ユーロ）に達し、2021年の3,663億米ドル（3,239億5,000万ユーロ）から約4.95％増加したと報告しました。このように、バイオ医薬品産業の成長が経口タンパク質とペプチド市場の拡大に寄与しています。

経口タンパク質とペプチド市場の主な企業は、患者のアドヒアランスと快適性を向上させるため、経口セマグルチドのような革新的な製品の開発に注力しています。経口セマグルチドは、経口タンパク質とペプチド分野での大きな進歩を象徴しています。グルカゴン様ペプチド-1（GLP-1）受容体作動薬であるセマグルチドは、従来、2型糖尿病や最近では肥満症の治療のために注射剤で投与されていました。例えば、2022年1月、インドのヘルスケア企業であるノボ・ノルディスク・インドは、世界初の経口セマグルチドを発売し、糖尿病治療における大きなブレークスルーを示しました。従来は注射剤のみであったこのGLP-1受容体アナログ製剤は、2型糖尿病の管理に、より簡便な経口剤という選択肢を提供することになりました。この開発は、糖尿病治療に革命をもたらすだけでなく、将来の経口インスリン製剤の革新に道を開くものであり、より効果的で患者にやさしい治療の選択肢をもたらす可能性があります。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界経口タンパク質とペプチド PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の経口タンパク質とペプチド市場：成長率分析
• 世界の経口タンパク質とペプチド市場の実績：規模と成長, 2019-2024
• 世界の経口タンパク質とペプチド市場の予測：規模と成長, 2024-2029, 2034F
• 世界経口タンパク質とペプチド総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の経口タンパク質とペプチド市場薬剤の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• リナクロチド
• カルシトニン
• インスリン
• プレカナチド
• オクトレオチド
• 世界の経口タンパク質とペプチド市場生物学的標的別、実績と予測, 2019-2024, 2024-2029F, 2034F
• グアニル酸シクラーゼC（GC-C）
• インスリン受容体
• シュウ酸
• その他の生物学的標的
• 世界の経口タンパク質とペプチド市場作用機序別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 受容体刺激
• 基質の分解
• その他の作用機序
• 世界の経口タンパク質とペプチド市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 胃腸障害
• 骨疾患
• 神経疾患
• 糖尿病
• 代謝障害
• ホルモン障害
• がん
• 世界の経口タンパク質とペプチド市場リナクロチドの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 過敏性腸症候群（IBS）の適応症
• 慢性特発性便秘（CIC）の適応症
• 世界の経口タンパク質とペプチド市場カルシトニンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• カルシトニン-サーモン
• 合成カルシトニン
• 骨粗鬆症治療のためのカルシトニン
• 世界の経口タンパク質とペプチド市場インスリンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 速効型インスリン
• 長時間作用型インスリン
• 複合インスリン製剤
• 経口インスリン製剤
• 世界の経口タンパク質とペプチド市場プレカナチドの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 慢性特発性便秘（CIC）の適応症
• 便秘を伴う過敏性腸症候群（IBS-C）の適応症
• 世界の経口タンパク質とペプチド市場オクトレオチドの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 長時間作用型オクトレオチド製剤
• 短時間作用型オクトレオチド製剤
• 先端巨大症および神経内分泌腫瘍の適応

第7章 地域別・国別分析

• 世界の経口タンパク質とペプチド市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の経口タンパク質とペプチド市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 経口タンパク質とペプチド市場：競合情勢
• 経口タンパク質とペプチド市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Sanofi S.A.
• AstraZeneca PLC
• Novartis AG
• GlaxoSmithKline PLC
• Eli Lilly and Company
• Amgen Inc.
• Novo Nordisk A/S
• Ipsen S.A.
• Biocon Limited
• Xeris Pharmaceuticals Inc.
• Adocia S.A.
• Zealand Pharma A/S
• Diabetology Ltd.
• Oramed Pharmaceuticals Inc.
• Palatin Technologies Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 経口タンパク質とペプチド市場2029：新たな機会を提供する国
• 経口タンパク質とペプチド市場2029：新たな機会を提供するセグメント
• 経口タンパク質とペプチド市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Oral Proteins and Peptides refer to therapeutic proteins and peptides administered orally, typically in pills, capsules, or other ingestible formats. These biologically active molecules are designed to treat various medical conditions by leveraging their specific actions within the body.

The main drug types of oral proteins and peptides are linaclotide, calcitonin, insulin, plecanatide, and octreotide. The biological targets are guanylate cyclase-c (gc-c), insulin receptor, oxalate, and others, and the different mechanisms of action are receptor stimulation, substrate degradation, and others. It is used for various applications such as gastrointestinal disorders, bone disease, neurological disorders, diabetes, metabolic disorders, hormonal disorders, and cancer.

The oral proteins and peptides market research report is one of a series of new reports from The Business Research Company that provides oral proteins and peptides market statistics, including oral proteins and peptides industry global market size, regional shares, competitors with a oral proteins and peptides market share, detailed oral proteins and peptides market segments, market trends and opportunities, and any further data you may need to thrive in the oral proteins and peptides industry. This oral proteins and peptides market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The oral proteins and peptides market size has grown exponentially in recent years. It will grow from $1.27 $ billion in 2024 to $1.56 $ billion in 2025 at a compound annual growth rate (CAGR) of 22.7%. The growth in the historic period can be attributed to the rising prevalence of chronic diseases, increasing investments in biotechnology for the development of oral protein-based treatments, growing consumer preference for non-invasive treatments, increasing biopharmaceutical industry, and rising focus on personalized medicine.

The oral proteins and peptides market size is expected to see exponential growth in the next few years. It will grow to $3.49 $ billion in 2029 at a compound annual growth rate (CAGR) of 22.3%. The growth in the forecast period can be attributed to increasing focus on patient-centric drugs, increasing prevalence of the geriatric population, rising healthcare expenditure, growing need for diagnostics in cancer, and rising preference for oral drugs. Major trends in the forecast period include development of novel oral peptides with enhanced stability and efficacy, integration of artificial intelligence in drug discovery processes for oral formulations, advanced medical treatments, advancements in drug delivery technologies, and innovative oral insulin formulations.

The expanding biopharmaceutical industry is expected to drive the growth of the oral proteins and peptides market in the future. This sector, part of the broader pharmaceutical industry, focuses on developing, producing, and commercializing drugs derived from biological sources. The growth of the biopharmaceutical industry is fueled by advancements in biotechnology, increased demand for personalized medicine, a rise in chronic diseases, and higher investment in research and development. Oral proteins and peptides offer the potential for non-invasive therapeutic delivery, improving patient compliance and reducing the need for injections. They can target specific diseases with enhanced stability and absorption in the digestive system. For example, in June 2023, the European Federation of Pharmaceutical Industries and Associations (EFPIA) reported that total biopharmaceutical production in Europe reached $384.2 billion (€340 billion) in 2022, a rise of about 4.95% from $366.3 billion (€323.95 billion) in 2021. Thus, the growth of the biopharmaceutical industry is contributing to the expansion of the oral proteins and peptides market.

Key companies in the oral proteins and peptides market are focusing on developing innovative products such as Oral Semaglutide to improve patient adherence and comfort. Oral Semaglutide represents a significant advancement in the field of oral proteins and peptides. As a glucagon-like peptide-1 (GLP-1) receptor agonist, semaglutide was traditionally administered via injection for the treatment of type 2 diabetes and, more recently, obesity. For example, in January 2022, Novo Nordisk India, a healthcare company based in India, introduced the world's first oral semaglutide, marking a major breakthrough in diabetes treatment. Previously available only in injectable form, this GLP-1 receptor analogue now offers a more convenient oral option for managing type 2 diabetes. This development not only revolutionizes diabetes care but also paves the way for future innovations in oral insulin formulations, potentially leading to more effective and patient-friendly treatment options.

In April 2023, Chiesi Farmaceutici S.p.a., an Italy-based pharmaceutical company, acquired Amryt Pharma Plc for an undisclosed sum. This acquisition allows Chiesi to leverage Amryt's unique products and promising pipeline, bolstering its commitment to rare diseases and expanding its biopharmaceutical expertise. Amryt Pharma Plc, based in the UK, specializes in oral proteins and peptides.

Major companies operating in the oral proteins and peptides market are Pfizer Inc., Johnson & Johnson Services Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., AstraZeneca PLC, Novartis AG, GlaxoSmithKline PLC, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Ipsen S.A., Biocon Limited, Xeris Pharmaceuticals Inc., Adocia S.A., Zealand Pharma A/S, Diabetology Ltd., Oramed Pharmaceuticals Inc., Palatin Technologies Inc., Entera Bio Ltd.

North America was the largest region in the oral proteins and peptides market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral proteins and peptides market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the oral proteins and peptides market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The oral proteins and peptides market consists of sales of protein supplements, peptide-based drugs, and therapeutic formulations designed for oral administration. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Oral Proteins And Peptides Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on oral proteins and peptides market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for oral proteins and peptides ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The oral proteins and peptides market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Linaclotide; Calcitonin; Insulin; Plecanatide; Octreotide
• 2) By Biological Target: Guanylate Cyclase-C (GC-C); Insulin Receptor; Oxalate; Other Biological Targets
• 3) By Mechanism Of Action: Receptor Stimulation; Substrate Degradation; Other Mechanisms Of Action
• 4) By Application: Gastrointestinal Disorders; Bone Disease; Neurological Disorders; Diabetes; Metabolic Disorders; Hormonal Disorder; Cancer
• Subsegments:
• 1) By Linaclotide: Indications For Irritable Bowel Syndrome (IBS); Indications For Chronic Idiopathic Constipation (CIC)
• 2) By Calcitonin: Calcitonin-Salmon; Synthetic Calcitonin; Calcitonin for Osteoporosis Treatment
• 3) By Insulin: Rapid-Acting Insulin; Long-Acting Insulin; Combination Insulin Products; Oral Insulin Formulations
• 4) By Plecanatide: Indications For Chronic Idiopathic Constipation (CIC); Indications For Irritable Bowel Syndrome With Constipation (IBS-C)
• 5) By Octreotide: Long-Acting Octreotide Formulations; Short-Acting Octreotide Formulations; Indications For Acromegaly And Neuroendocrine Tumors
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; Roche Holding AG; Merck & Co. Inc.; AbbVie Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Oral Proteins And Peptides Market Characteristics

3. Oral Proteins And Peptides Market Trends And Strategies

4. Oral Proteins And Peptides Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Oral Proteins And Peptides Growth Analysis And Strategic Analysis Framework

• 5.1. Global Oral Proteins And Peptides PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Oral Proteins And Peptides Market Growth Rate Analysis
• 5.4. Global Oral Proteins And Peptides Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Oral Proteins And Peptides Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Oral Proteins And Peptides Total Addressable Market (TAM)

6. Oral Proteins And Peptides Market Segmentation

• 6.1. Global Oral Proteins And Peptides Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Linaclotide
• Calcitonin
• Insulin
• Plecanatide
• Octreotide
• 6.2. Global Oral Proteins And Peptides Market, Segmentation By Biological Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Guanylate Cyclase-C (GC-C)
• Insulin Receptor
• Oxalate
• Other Biological Targets
• 6.3. Global Oral Proteins And Peptides Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Receptor Stimulation
• Substrate Degradation
• Other Mechanisms Of Action
• 6.4. Global Oral Proteins And Peptides Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Gastrointestinal Disorders
• Bone Disease
• Neurological Disorders
• Diabetes
• Metabolic Disorders
• Hormonal Disorder
• Cancer
• 6.5. Global Oral Proteins And Peptides Market, Sub-Segmentation Of Linaclotide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Indications For Irritable Bowel Syndrome (IBS)
• Indications For Chronic Idiopathic Constipation (CIC)
• 6.6. Global Oral Proteins And Peptides Market, Sub-Segmentation Of Calcitonin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Calcitonin-Salmon
• Synthetic Calcitonin
• Calcitonin for Osteoporosis Treatment
• 6.7. Global Oral Proteins And Peptides Market, Sub-Segmentation Of Insulin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Rapid-Acting Insulin
• Long-Acting Insulin
• Combination Insulin Products
• Oral Insulin Formulations
• 6.8. Global Oral Proteins And Peptides Market, Sub-Segmentation Of Plecanatide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Indications For Chronic Idiopathic Constipation (CIC)
• Indications For Irritable Bowel Syndrome With Constipation (IBS-C)
• 6.9. Global Oral Proteins And Peptides Market, Sub-Segmentation Of Octreotide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Long-Acting Octreotide Formulations
• Short-Acting Octreotide Formulations
• Indications For Acromegaly And Neuroendocrine Tumors

7. Oral Proteins And Peptides Market Regional And Country Analysis

• 7.1. Global Oral Proteins And Peptides Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Oral Proteins And Peptides Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Oral Proteins And Peptides Market

• 8.1. Asia-Pacific Oral Proteins And Peptides Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Oral Proteins And Peptides Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Oral Proteins And Peptides Market, Segmentation By Biological Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Oral Proteins And Peptides Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Oral Proteins And Peptides Market

• 9.1. China Oral Proteins And Peptides Market Overview
• 9.2. China Oral Proteins And Peptides Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Oral Proteins And Peptides Market, Segmentation By Biological Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Oral Proteins And Peptides Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Oral Proteins And Peptides Market

• 10.1. India Oral Proteins And Peptides Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Oral Proteins And Peptides Market, Segmentation By Biological Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Oral Proteins And Peptides Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Oral Proteins And Peptides Market

• 11.1. Japan Oral Proteins And Peptides Market Overview
• 11.2. Japan Oral Proteins And Peptides Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Oral Proteins And Peptides Market, Segmentation By Biological Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Oral Proteins And Peptides Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Oral Proteins And Peptides Market

• 12.1. Australia Oral Proteins And Peptides Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Oral Proteins And Peptides Market, Segmentation By Biological Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Oral Proteins And Peptides Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Oral Proteins And Peptides Market

• 13.1. Indonesia Oral Proteins And Peptides Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Oral Proteins And Peptides Market, Segmentation By Biological Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Oral Proteins And Peptides Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Oral Proteins And Peptides Market

• 14.1. South Korea Oral Proteins And Peptides Market Overview
• 14.2. South Korea Oral Proteins And Peptides Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Oral Proteins And Peptides Market, Segmentation By Biological Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Oral Proteins And Peptides Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Oral Proteins And Peptides Market

• 15.1. Western Europe Oral Proteins And Peptides Market Overview
• 15.2. Western Europe Oral Proteins And Peptides Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Oral Proteins And Peptides Market, Segmentation By Biological Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Oral Proteins And Peptides Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Oral Proteins And Peptides Market

• 16.1. UK Oral Proteins And Peptides Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Oral Proteins And Peptides Market, Segmentation By Biological Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Oral Proteins And Peptides Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Oral Proteins And Peptides Market

• 17.1. Germany Oral Proteins And Peptides Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Oral Proteins And Peptides Market, Segmentation By Biological Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Oral Proteins And Peptides Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Oral Proteins And Peptides Market

• 18.1. France Oral Proteins And Peptides Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Oral Proteins And Peptides Market, Segmentation By Biological Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Oral Proteins And Peptides Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Oral Proteins And Peptides Market

• 19.1. Italy Oral Proteins And Peptides Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Oral Proteins And Peptides Market, Segmentation By Biological Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Oral Proteins And Peptides Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Oral Proteins And Peptides Market

• 20.1. Spain Oral Proteins And Peptides Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Oral Proteins And Peptides Market, Segmentation By Biological Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Oral Proteins And Peptides Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Oral Proteins And Peptides Market

• 21.1. Eastern Europe Oral Proteins And Peptides Market Overview
• 21.2. Eastern Europe Oral Proteins And Peptides Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Oral Proteins And Peptides Market, Segmentation By Biological Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Oral Proteins And Peptides Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Oral Proteins And Peptides Market

• 22.1. Russia Oral Proteins And Peptides Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Oral Proteins And Peptides Market, Segmentation By Biological Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Oral Proteins And Peptides Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Oral Proteins And Peptides Market

• 23.1. North America Oral Proteins And Peptides Market Overview
• 23.2. North America Oral Proteins And Peptides Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Oral Proteins And Peptides Market, Segmentation By Biological Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Oral Proteins And Peptides Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Oral Proteins And Peptides Market

• 24.1. USA Oral Proteins And Peptides Market Overview
• 24.2. USA Oral Proteins And Peptides Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Oral Proteins And Peptides Market, Segmentation By Biological Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Oral Proteins And Peptides Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Oral Proteins And Peptides Market

• 25.1. Canada Oral Proteins And Peptides Market Overview
• 25.2. Canada Oral Proteins And Peptides Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Oral Proteins And Peptides Market, Segmentation By Biological Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Oral Proteins And Peptides Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Oral Proteins And Peptides Market

• 26.1. South America Oral Proteins And Peptides Market Overview
• 26.2. South America Oral Proteins And Peptides Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Oral Proteins And Peptides Market, Segmentation By Biological Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Oral Proteins And Peptides Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Oral Proteins And Peptides Market

• 27.1. Brazil Oral Proteins And Peptides Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Oral Proteins And Peptides Market, Segmentation By Biological Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Oral Proteins And Peptides Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Oral Proteins And Peptides Market

• 28.1. Middle East Oral Proteins And Peptides Market Overview
• 28.2. Middle East Oral Proteins And Peptides Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Oral Proteins And Peptides Market, Segmentation By Biological Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Oral Proteins And Peptides Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Oral Proteins And Peptides Market

• 29.1. Africa Oral Proteins And Peptides Market Overview
• 29.2. Africa Oral Proteins And Peptides Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Oral Proteins And Peptides Market, Segmentation By Biological Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Oral Proteins And Peptides Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Oral Proteins And Peptides Market Competitive Landscape And Company Profiles

• 30.1. Oral Proteins And Peptides Market Competitive Landscape
• 30.2. Oral Proteins And Peptides Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Oral Proteins And Peptides Market Other Major And Innovative Companies

• 31.1. Sanofi S.A.
• 31.2. AstraZeneca PLC
• 31.3. Novartis AG
• 31.4. GlaxoSmithKline PLC
• 31.5. Eli Lilly and Company
• 31.6. Amgen Inc.
• 31.7. Novo Nordisk A/S
• 31.8. Ipsen S.A.
• 31.9. Biocon Limited
• 31.10. Xeris Pharmaceuticals Inc.
• 31.11. Adocia S.A.
• 31.12. Zealand Pharma A/S
• 31.13. Diabetology Ltd.
• 31.14. Oramed Pharmaceuticals Inc.
• 31.15. Palatin Technologies Inc.

32. Global Oral Proteins And Peptides Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Oral Proteins And Peptides Market

34. Recent Developments In The Oral Proteins And Peptides Market

35. Oral Proteins And Peptides Market High Potential Countries, Segments and Strategies

• 35.1 Oral Proteins And Peptides Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Oral Proteins And Peptides Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Oral Proteins And Peptides Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer